VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. AQSAQSZF (“Aequus” or the “Company“) announces that the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its management’s discussion and analysis relating to the Annual Financial Statements (collectively, the “Annual Disclosure“) will be delayed beyond the filing deadline of May 2, 2022.
The Company’s late filing of the Annual Disclosure is due to delays in its audit procedure and receiving timely responses to its audit requests from third parties. The Company’s management is diligently working through the various issues in order to expedite the finalization of the Annual Disclosure.
The Company fully expects to file the Annual Disclosure on or before Friday, May 6, 2022, and intends to provide updates on further developments in respect of this matter promptly following their occurrence.
About Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc. AQSAQSZF is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based…